Stock Financial Ratios, Dividends, Split History

BRK.A / Berkshire Hathaway, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)402,089,712.86
Enterprise Value ($M)383,635,585.45
Book Value ($M)347,401.00
Book Value / Share258.08
Price / Book1,154.45
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Shares Outstanding 1,344,332,039
Common Shares Outstanding2 748,745
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.13
Return on Assets (ROA)0.07
Return on Equity (ROE)0.16
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Sales Revenue Net132,900,000,000.00
Cargo And Freight Revenue And Regulated And Unregulated Operating Revenue0.00
Other Revenues0.00
Revenue Other Financial Services0.00
Net Income45,353.00
Cash Flow Statement (mra) ($M)
Cash From Operations45,776.00
Cash from Investing-41,091.00
Cash from Financing-41,091.00
Identifiers and Descriptors
Central Index Key (CIK)1067983
Related CUSIPS
084990175 846707024 084670991

Split History

Stock splits are used by Berkshire Hathaway, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

Should You Invest in Emerging Market ETFs Right Now?

10h investorplace
If I’ve learned anything, it’s that a majority of people don’t like to leave their comfort zone — whether that’s dealing with insecurity, seeking a new job or making an investment decision. On that last note, many investors prefer to invest in what they know. While they may know the difference between an ETF and a mutual fund, many prefer to avoid emerging market ETFs. (374-1)

Buffett, Bezos and Dimon Found Their CEO -- Now Comes the Hard Part | InvestorPlace

12h investorplace
If you’re a medical practitioner being asked by Jeff Bezos, Warren Buffett and Jamie Dimon to head up a potentially historical healthcare initiative that conveniently doesn’t have to worry about making money has got to feel like winning the Powerball lottery. (139-0)

Greatest Stock Picker Of All Time: Buffett Or Lynch?

12h valuewalk
Get the entire 10-part series on Warren Buffett in PDF. Save it to your desktop, read it on your tablet, or email to your colleagues (50-0)

Inside dinner with Warren Buffett and Bill Gates at Piccolo in Omaha

14h cnbc
As the CEO of Berkshire Hathaway, Buffett built what was once a struggling textile mill into a financial conglomerate now worth $472 billion. Gates co-founded Microsoft, which helped revolutionize personal computing and boasts a market cap of more than $767 billion. Both captains of industry are billionaires many times over: Buffett is worth $81.4 billion according to Forbes, and Bill Gates is worth $92. (34-0)

Warren Buffett's favorite book on investing

14h cnbc
Despite a generally positive economic outlook, one asset manager warns that signs of a potential market crash are now appearing. (34-0)

CUSIP: 084670108